1
弘前大学 医学部 泌尿器科学教室
腎癌術後フォローアップ・プロトコール
Lam JS, Shvarts O, Leppert JT, Pantuck AJ, Figlin RA, Belldegrun AS.
J Urol 174. 466-472, 2005
Division of Urologic Oncology, the Department of Urology, David Geffen School of Medicine at
University of California-Los Angeles, Los Angeles, California 90095, USA.
Postoperative surveillance protocol for patients with localized and
locally advanced renal cell carcinoma based on validated prognotic
nomogram and risk group stratification system
Since 2005.9
【参考文献】
2
Hirosaki Risk Group Assignment
pN stage
O or 1
pT stage
pT1
Grade
pT2-4
G1-2
G3
G1-3
Low Risk
High Risk
pN0
pN1
:
3
術後フォローアップ・スケジュール
3M
6M
1y
1.5y
2y
2.5y
3y
3.5y
4y
4.5y
5y
7y
9y
Low
肺CT
採血
肺CT
腹CT
採血
肺CT
採血
肺CT
腹CT
採血
肺CT
採血
High
肺CT
腹CT
採血
肺CT
腹CT
採血
肺CT
腹CT
採血
肺CT
腹CT
採血
肺CT
腹CT
採血
肺CT
腹CT
採血
肺CT
腹CT
採血
肺CT
腹CT
採血
肺CT
腹CT
採血
肺CT
腹CT
採血
N+
肺CT
腹CT
採血
肺CT
腹CT
採血
肺CT
腹CT
採血
肺CT
腹CT
採血
肺CT
腹CT
採血
肺CT
腹CT
採血
肺CT
腹CT
採血
肺CT
腹CT
採血
肺CT
腹CT
採血
肺CT
腹CT
採血
肺CT
腹CT
採血
肺CT
腹CT
採血
肺CT
腹CT
採血
採血項目:末梢血、血沈、生化学(肝胆道系・腎機能・電解質・CRP)
定期検査ごとに問診と身体所見を確認する。
4
Hirosaki Risk Group Assignment について
• 「なるべくカンタンに」、「誰でもわかるように」を目標に術
後フォローアップのプロトコールを作成した。
• 以下に示すように519例の検討によるEvidenceを元に
作成している。原著ではLow、Intermediate、Highに分
けているが、 IntermediateとHighは予後不良群と考えら
れるため、カテゴリーの単純化も含め、Highにまとめた。
• PSも議論となるが、簡便化のため今回のプロトコールか
らは外した。ただ、のちの解析に必要となる場合もあるた
め、退院サマリーには記載する。
5
Lam JS, Shvarts O, Leppert JT, Pantuck AJ, Figlin RA, Belldegrun AS.J Urol 174. 466-472, 2005
Division of Urologic Oncology, the Department of Urology, David Geffen School of Medicine at University of California-Los Angeles, Los Angeles, California 90095, USA.
PURPOSE: We created an evidence based postoperative surveillance protocol for patients with localized and locally advanced renal cell
carcinoma (RCC) based on a risk group stratification system.
MATERIALS AND METHODS: 559 patients undergoing surgery for localized and ocally advanced RCC were stratified into low risk (LR),
intermediate risk (IR) and high risk (HR) groups based on the University of California-Los Angeles Integrated Staging System (UISS). Tumor recurrences were identified and categorized according to time and location.
RESULTS: Patients with localized disease had a lower 5-year recurrence rate than patients with locally advanced (nodal) disease (27.6% vs
64%, p <0.0001). Patients in the LR, IR, and HR groups following nephrectomy demonstrated 5-year recurrence-free rates of 90.4%, 61.8%, and 41.9%, respectively (p <0.0001), and median times to recurrence of 28.9, 17.8 and 9.5 months, respectively (p <0.0001). Chest and abdomen recurrences comprised of 75% and 37.5%, 77.4% and 58.1%, and 45.2% and 67.7% of recurrences in the LR, IR and HR groups, respectively. In patients with node positive disease, chest and abdomen comprised of 58.8% and 76.5% of recurrences, respectively.
Patients undergoing partial nephrectomy did not demonstrate a greater rate of local or distant recurrence compared with patients undergoing radical nephrectomy.
CONCLUSIONS: Significant differences in incidence and time to recurrence following surgical resection for RCC mandates unique
surveillance protocols for patients in each of the UISS risk groups. LR group patients should be followed for at least 5 years, whereas IR and HR group patients require longer surveillance. HR group patients require more stringent abdominal surveillance, whereas LR group patients should emphasize the chest. Patients with nodal disease also require stringent followup. Patients undergoing partial nephrectomy for
localized disease can be followed according to the same UISS risk group based protocol.